• U.S. Centers for Medicare & Medicaid Services has approved coverage for Dexcom G7, the most accurate,¹ easy-to-use CGM system that helps people with diabetes gain greater control of their health.
• Introduced to the world yesterday in a Super Bowl ad, Dexcom G7 eliminates routine fingersticks^* and builds on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C and increase time in range.^2-6
• The approval of Medicare coverage for Dexcom G7 further solidifies Dexcom as the most covered and reimbursed CGM brand on the market.⁷
• People with diabetes in the US, including Medicare patients, can visit Dexcom.com/G7 today to get started with Dexcom G7.

Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System will be covered for Medicare beneficiaries.^† Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, Dexcom G7 will be accessible to all Medicare patients with diabetes who meet the eligibility criteria when the system launches this Friday, Feb. 17.

“When we set out to design G7, our goal was simple: to make the most accurate, easy-to-use CGM available for as many people with diabetes as possible,” said Kevin Sayer, chairman, president and CEO of Dexcom. “The approval of Medicare coverage for G7 helps us deliver on that promise. Now Medicare patients with Type 1 and Type 2 diabetes will have access to the newest CGM technology that offers the most reliable, simple way to help people manage their diabetes more confidently.”

The most accurate,¹ easy to use CGM available will be covered by Medicare at launch.

With Dexcom G7, the #1 recommended CGM brand^8,9 now offers the most accurate¹ and simple way to help people gain greater control of their diabetes. Its low-profile, all-in-one wearable warms up faster than any other CGM on the market,^‡ sending real-time glucose readings automatically to a compatible smart device^§ or receiver, no painful fingersticks^* or burdensome scanning required. With an overall MARD of 8.2%, Dexcom G7 is the most accurate CGM on the market,¹ building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range.^2-6

People with diabetes in the US, including Medicare patients, can visit Dexcom.com/G7 today to get started with Dexcom G7. The system will be available on Feb. 17.

About Dexcom, Inc.

Dexcom, Inc. empowers people to take control of health through innovative continuous glucose monitoring systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom, visit dexcom.com/about-dexcom.

^*Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

^†Under Medicare’s DME fee schedule, reimbursement for CGMs, using CPT codes E2103 and A4239, is the same, regardless of CGM brand. Regulation at 42 CFR 410.152(b), stipulates that coinsurance for items of durable medical equipment is 20% of the allowed amount. ^‡Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. ^§Compatible smart devices sold separately. To view a list of compatible smart devices, visit dexcom.com/compatibility. ^||Compared to a prior generation Dexcom CGM System. ^¶An internet connection is required to send data to Dexcom Clarity. ^#User must first sync their Dexcom G7 data with the Dexcom Clarity app and consent to share their data with their healthcare provider. **Separate Follow app and internet connection required. Users should always confirm readings on the Dexcom CGM System app or receiver before making treatment decisions.

1 Dexcom, data on file, 2022. 2 Welsh JB, et al. J Diabetes Sci Technol. 2022:19322968221099879. 3 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39. 4 Beck RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Managed Markets Insights & Technology, LLC. MMIT Analytics, June 2022. 8 d&A US Q1 2021 Diabetes Connections Patient Panel Report.2021;69-72. 9 Seagrove HCP Survey Q1 2021. 2021;65. 10 Shah VN, et al. Diabetes Technol Ther. 2018;20(6):428-433.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005189/en/